• H. Dunbar Hoskins Jr., MDThe H. Dunbar Hoskins Jr., M.D. Center for Quality Eye Care was established as a quality of care and health policy research center that advances the accessibility to and appropriateness of eye care services. The work of the Hoskins Center will help ensure that patients continue to receive high quality, evidence-based eye care within a tightening economic environment that demands increased value for services provided.

  • from AAO OTAC Glaucoma Panel, Hoskins Center for Quality Eye Care
    Intravitreal injection of anti-VEGF agents results in an immediate and transient increase in IOP. A long-term increase in IOP also may be seen. Further studies are needed to determine at-risk populations and to determine the impact on glaucoma progression.
    Ophthalmic Technology Assessment
    from AAO OTAC Pediatric Ophthalmology/Strabismus Panel, Hoskins Center for Quality Eye Care
    Orthokeratology may be effective in slowing myopic progression for children and adolescents, with a potentially greater effect when initiated at an early age (6–8 years). Safety remains a concern because of the risk of potentially blinding microbial keratitis.
    Ophthalmic Technology Assessment
    from AAO OTAC Pediatric Ophthalmology/Strabismus Panel, Hoskins Center for Quality Eye Care
    There is limited evidence to support the safety and efficacy of β-blockers to promote regression of periocular hemangiomas. Additional research may confirm the best dosage and route of administration to maximize efficacy while minimizing side effects.
    Ophthalmic Technology Assessment
    from AAO OTAC Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Review of the literature indicates that intravitreal injection of anti-VEGF therapy is safe and effective for neovascular AMD over 2 years. Further research is needed to evaluate long-term safety and comparative efficacy of these agents.
    Ophthalmic Technology Assessment
    from AAO OTAC Glaucoma Panel, Hoskins Center for Quality Eye Care
    Structural glaucomatous damage can be detected by SD OCT. Optic nerve, RNFL, and macular parameters can help the clinician distinguish the anatomic changes that are associated with patients with glaucoma when compared with normal subjects.
    Ophthalmic Technology Assessment
    from AAO OTAC Glaucoma Panel, Hoskins Center for Quality Eye Care
    LPI increases angle width in all stages of PAC and has a good safety profile. Most PACS eyes do not receive further intervention, whereas many PAC and APAC eyes, and most PACG eyes, receive further treatment.
    Ophthalmic Technology Assessment
    from AAO OTAC Oculoplastics and Orbit Panel, Hoskins Center for Quality Eye Care
    The literature indicates that balloon dacryoplasty is a safe, effective procedure to address congenital nasolacrimal duct obstruction that persists after standard probings. The outcomes of this intervention are similar to those of lacrimal stenting.
    Ophthalmic Technology Assessment
    from AAO OTAC Oculoplastics and Orbit Panel, Hoskins Center for Quality Eye Care
    Botox, Meditoxin, and Xeomin are effective for the treatment of BEB. Meditoxin and Botox have equivalent effectiveness and incidence of adverse events for BEB and HFS. Higher doses of Botox and Dysport result in more adverse events.
    Ophthalmic Technology Assessment
    from AAO OTAC Pediatric Ophthalmology/Strabismus Panel, Hoskins Center for Quality Eye Care
    Silicone elastomer and RGP contact lenses were found to be effective for treating aphakia in children, although evidence was limited. The choice of which lens a practitioner prescribes should be based on the particular needs of each patient.
    Ophthalmic Technology Assessment
    from AAO OTAC Cornea and Anterior Segment Disorders Panel, Hoskins Center for Quality Eye Care
    Evidence demonstrates DMEK is a safe and effective treatment for endothelial failure. DMEK induces less refractive error with similar surgical risks and EC loss compared with DSEK and is superior in recovery time, outcomes and rejection rates.
    Ophthalmic Technology Assessment
    from AAO OTAC Oculoplastics and Orbit Panel, Hoskins Center for Quality Eye Care
    Orbital implants resulted in excellent motility after enucleation surgery. Major complications were rare, and infection was uncommon. Data were inconclusive on motility and comparisons of porous and nonporous implants.
    Ophthalmic Technology Assessment
    from AAO OTAC Oculoplastics and Orbit Panel, Hoskins Center for Quality Eye Care
    Evidence demonstrates that local control, disease-free survival and overall survival are good with radiation treatment for MALT lymphomas. Treatment results of non-MALT lymphomas using radiotherapy were not as favorable as the MALT lymphomas results.
    Ophthalmic Technology Assessment
    from AAO OTAC Pediatric Ophthalmology/Strabismus Panel, Hoskins Center for Quality Eye Care
    Level 1 evidence supports the use of atropine for the prevention of myopia progression in children. Myopic rebound after discontinuation is minimized with low atropine dosages. Most robust studies have been conducted in Asian populations.
    Ophthalmic Technology Assessment
    from AAO OTAC Glaucoma Panel, Hoskins Center for Quality Eye Care
    Effective disinfection of tonometer tips against adenovirus and HSV is best supplied by sodium hypochlorite (dilute bleach). Tonometer prisms should be examined regularly for damage, which can pose risk for introducing infectious agents.
    Ophthalmic Technology Assessment
    from AAO OTAC Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Strong evidence indicates intravitreal pharmacotherapy with anti-VEGF agents is a safe and effective therapy for ME secondary to BRVO. Intravitreal corticosteroids are associated with greater side effects and VA is less optimal with laser photocoagulation treatments.
    Ophthalmic Technology Assessment
    from AAO OTAC Pediatric Ophthalmology/Strabismus Panel, Hoskins Center for Quality Eye Care
    Evidence-based review indicates that intravitreal anti-VEGF therapy is as effective as laser photocoagulation therapy for achieving regression of acute ROP. Long-term systemic and neurodevelopmental effects on premature infants remain unknown.
    Ophthalmic Technology Assessment
    from AAO OTAC Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Evidence suggests that combination intravitreal foscarnet and systemic therapy may be more effective than systemic therapy in the treatment of acute retinal necrosis (ARN). While PCR testing reliably confirms ARN cases, antiviral treatment must not be delayed.
    Ophthalmic Technology Assessment
    from AAO OTAC Pediatric Ophthalmology/Strabismus Panel, Hoskins Center for Quality Eye Care
    An evidence-based review assessing the accuracy of available retinopathy of prematurity (ROP) predictive models to detect clinically significant ROP. Examines the risks and limitations of various models in allowing the reduction of burdensome ROP screening examinations.
    Ophthalmic Technology Assessment
    from AAO OTAC Oculoplastics and Orbit Panel, Hoskins Center for Quality Eye Care
    Evidence-based review on the effectiveness of oral antibiotics in the management of ocular surface disease that arises from disorders of the meibomian glands and to assess the efficacy of oral antibiotics in the management of this common ocular disease
    Ophthalmic Technology Assessment
    from AAO OTAC Retina/Vitreous Panel, Hoskins Center for Quality Eye Care
    Evidence-based review on the effectiveness of routine nonsteroidal anti-inflammatory drug (NSAID) treatment to prevent vision loss from cystoid macular edema at ≥3 months after cataract surgery
    Ophthalmic Technology Assessment